Member Info for notaflipper

I believe that the initial listing price was 11p for NIPT but perhaps some VIY holder can correct me. Despite the negativity which is surprising given the partnerships now in place with Illumina and TMO in a multi-billion dollar industry the Company has doubled its market capitalisation during that time though obviously many LTHs are still heavily under water. I am a bit surprised as to how much this has been over-sold given a share dilution of only 5% but there you go. This is also because the current sp below the placing price and below Steve Myers latest purchase. I suspect that updated broker's report was targeted for 'early' November to coincide with the TDIM change. The delay in the trading update and in the broker's report suggest that there has been a background delay however the fact that they went ahead with the TDIM change rather than delaying this till the 3rd Dec suggests that this news is not far off. For me Peter Collins to step down immediately was very strange. It would seem for Peter Collins to leave in the midst of negotiations with TMO as well as potential oncology/reproductive health contracts given his past history in brokering these deals and in commercial negotiations. Although there has been some small PI holder selling in recent weeks I suspect that the 100k purchases also allude to larger positions being taken.

Bit of a novel approach taken by YourGene Health to change its name without any publicity (e.g. TW article) nor accompanying updated broker forecasts. I imagine that that all of this has been delayed whilst they get some background deal sorted (probably TMO exercise of warrants) and then we should then receive new broker forecasts and further commercial news on third party partnerships. Have to imagine that news should not be far off now. Key thing would be the deal agreed with TMO as to the exercise price of warrants and the debt forgivement. Whereas the former should create a new floor at a higher sp level the latter should clear up the balance sheet. With the Half Year results due to on 3rd Dec one would have to expect news shortly

You have to press the Go button as well.

Vigo were true to form today :-)

Quite a positive RNS aside. Let's see if we get more on the below on potential new products and new contracts in the next few weeks in order to publicise the name change:

"Our technical expertise in genetic test development, partnerships with DNA technology majors and expanding global footprint also put us in a strong position to develop additional products both within reproductive health and oncology.

"I look forward to providing further updates on the commercialisation of the Group as we expand organically, through distribution and licensing agreements, and via third party partnerships."

Yourgene Health PLC Change of Name to Yourgene Health plc
07/11/2018 7:00am
UK Regulatory (RNS & others)

Premaitha (LSE:NIPT)
Intraday Stock Chart
Today : Wednesday 7 November 2018

TIDMYGEN
RNS Number : 5273G
Yourgene Health PLC
07 November 2018
Premaitha Health plc
("Premaitha" or the "Group")
Change of Name to Yourgene Health plc
&
Change of Website Address
Manchester, UK - 7 November 2018: Premaitha Health plc, the international molecular diagnostics group which commercialises genetic products and services that positively impact human health, is pleased to confirm the renaming of the Group as Yourgene Health plc ("Yourgene Health").
Further to the special resolution approved at the Group's Annual General Meeting on 25 October 2018, the Group's name has been changed to Yourgene Health plc and trading in the Group's shares under the new name and TIDM, "YGEN", will commence at 8.00 a.m. today. The Group's website is now available at www.yourgene-health.com.
The change of name reflects the Group's broadened product development and research service capabilities which extend across the lifecycle of DNA test development and commercialisation.
Yourgene Health's ongoing strategic priorities include:
-- developing and commercialising genetic products and services that positively impact human health;
-- driving worldwide sales of the Group's non-invasive prenatal testing ("NIPT") products and services by targeting further expansion through direct and key distribution channels to expand the geographic footprint;
-- continuing to offer highly customer-focused NIPT products and services which support all types of customer - irrespective of size, geography and market maturity - in partnership with leading DNA technology providers;
-- leveraging the Group's technical and regulatory expertise and partnerships to extend its genetic testing offering into complementary areas of reproductive health and oncology, both with owned intellectual property and as a third-party collaborator; and
-- supporting diagnostic majors and bioinformatics specialists with in vitro diagnostic product contract development partnerships.
Shareholdings will be unaffected by the change of name and existing share certificates should be retained as they will remain valid for all purposes. Any new share certificates issued will bear the name Yourgene Health plc.

Lyn Rees, Chief Executive Officer of Yourgene Health, commented: "Our change of name to Yourgene Health marks the beginning of an exciting new period for the Group. It reflects our broadened capabilities within the genetic testing universe and the combining of the Premaitha and Yourgene Bioscience businesses.
"Within the NIPT segment, we are aggressively targeting further expansion through distribution and licensing partnerships. The consolidated Group is now well-placed to deliver services to a global market and maximise its revenue potential.
"Our technical expertise in genetic test development, partnerships with DNA technology majors and expanding global footprint also put us in a strong position to develop additional products both within reproductive health and oncology.
"I look forward to providing further updates on the commercialisation of the Group as we expand organically, through distribution and licensing agreements, and via third party partnerships."

Cheers for this.

The Investor meeting on the 16th suggested an updated trading statement by the 25th October and then an updated broker's report in 'early' November. Obviously the former was more of a recycled statement but I would have imagined some development to initiate the latter (e.g. new contract/product or TMO deal).

It would be difficult for them to back-stop everything to the 3rd Dec and I genuinely hope that's not the intention.

For me Peter Collins to step down immediately was very strange. It would seem for Peter Collins to leave in the midst of negotiations with TMO as well as potential oncology/reproductive health contracts given his past history in brokering these deals and in commercial negotiations. Similarly it would be strange for him not to stay on at least for a few more weeks unless the company was not be relaunched imminently. However given the narrative here it's anyone's guess as to what happens.

In addition to the help that this gives to cost management I take this news as reorganisation before the Company relaunch which is good news. There has been a lot of potential news already forward trailed in some of the company presentations; such as Company Name/TDIM Change, reproductive health product news, TMO warrants conversion/debt forgiveness, and more detail on the revised company strategy etc. I would have to imagine that some of these would at the very least have an internal target to be released by Half Year results as it wouldn't make sense to have the Half Year report having another Company Name etc. So it will be interesting to see what else is achieved by then as well as to publicise relaunch. I suspect by now a revised Articles of Association for the Company is being prepared and we should hopefully get a timeline issued shortly to the Company relaunch.

Although it is never great to celebrate a person's departure from their job I think this is good news and inevitable. Since Hayden Jeffreys (Group Commercial Director) appointment there has been too much potential overlap with Chief Commercial Officer (Nick Claxton) and Chief Business Officer (Peter Collins) roles. So it is good to see that IR and the new CEO have understood this challenge. This should help the cost management efforts as well. His departure shouldn't affect any commercial regeneration post litigation release and is opportune in advance of the company relaunch which I would suggest will happen in the next 3 weeks in advance of the Half Year results.

Although these posts on ANGL and CPT are nice to see on other companies boards and I guess achieved their purpose in an effort to raise publicity to RNS issued about them we should also appreciate key differences in underlying technology. Neither of these products rely on NGS from my understanding. The Concepta product being a home test with an app and the Angle product trying a different test approach than Cell Free DNA hence not needing the IONA test of multi-parallel sequencing. This would be important from Illumina/TMO's perspective in buying in to any future product development. However let us see as its still early days for both of these companies which roughly are 5 years behind Premaitha / YourGene - and we LTHs all know what can happen in the interim. I also accept that Premaitha/YourGene could also find commercial partners to spread the costs of further commercialisation.

With a further 4 products at least planned in the next 2 years, and I suspect reproductive health announcement shortly, it should be interesting to see the revised strategic direction. Hopefully with AR (and Steve Myers) paying 10p last week on further placing subscriptions we should start seeing some news flow alongside a company relaunch which would have to happen in the next 3 weeks.

Concepta has a CE-IVD their product myLotus and allows women the ability to self-test to identify their optimal fertile days whereas (now) YourGene Health focuses on molecular diagnostics e.g. chromosol problems. So different parts of reproductive health. So for example part of the reproductive health products that the company will release is Pre-implantation genetic screening (PGS) which is a technique for testing whether embryos have any problems with their chromosomes, which is thought to be the most common reason why IVF treatment fails.

Could happen however good plug for CPT regardless.

The collaboration I would like to see is more strategic opportunities with Illumina. So for example from 2019 onward, in the UK the National Health Service will offer "all seriously ill children" whole-genome sequencing as part of their standard care, as well as to adults with certain rare diseases or "hard-to-treat" illnesses, the UK government said. In addition, patients will be asked to give consent for their genomic data to be analysed in an effort to develop new tests and treatments for cancer and rare diseases. The plan is for the NHS Genomic Medicine Service to expand on existing projects, such as the 100,000 Genomics Project and sequence 1 million whole genomics within five years.

So although Illumina have been the villain on this BB for the last 4 years, now as a strategic partner and YourGene Health now as a PPA licensee there could be other strategic opportunities before the Illumina CE-IVD is produced. However let's see as I suspect that more details of the strategic revision will be released in the next month.

With the BoD subscribing to 8.5m shares and Steve Myers Holding RNS showing a delta of 3.5m shares from his last threshold I would have imagined that as the placing raised £3.5m that some other IIs would have had to be part of the delta 35m shares. However to be honest it is fairly opaque.

It all depends if you think relaunch will happen by 3/12 or not.

If you believed that the BoD would want to deliver by the Half Year Results which are roughly 4 weeks away you would imagine that the next 3 weeks or so will be quite busy behind the scenes. I suspect that at the very least the Company Name change and TDIM will be changed by the Half Year results. So then that leaves whether they will be able to negotiate the TMO warrants conversion and broker forecast change by then. The delta would require to e driven by contract awards as well. Both have been set as aspirations for the BoD but we will have to see whether they can meet the Half Year Results statement and you would have imagined this would have to be at least an internal target for some milestones discussed.

snooze..
no commercial partner, no fda approval, 17 test patients, years away from phase 3 trials and commercialisation and trawling through other BBs to get PIs

there must have been some reason that steve myers (plus ar) paid 17% premium on sp last week on sp
Hopefully this month will see relaunch and recovery post year highs.

snooze..
no commercial partner, no fda approval, 17 test patients, years away from phase 3 trials and commercialisation and trawling through other BBs to get PIs

there must have been some reason that steve myers (plus ar) paid 17% premium on sp last week on sp
Hopefully this month will see relaunch and recovery post year highs.

Cheers for this. The reason this is also of interest is that the presenter Robert Henke who will be presenting for Premaitha originally comes from Illumina (where he was Director of Clinical Sales) and beforehand Affymetrix.
Changing of company's TDIM will need some sort of publicity (more than the usual TW bearcast I suppose) and we may see some the news that we had hoped to come by time of the AGM to come with this co-ordinated relaunch. Hopefully the coming week will confirm the date of the formal name change. I think that the market has yet to appreciate that if one steps back from some of the individual set-backs one can see that the BoD through the placing, Company Name change, warrants conversion/debt relief, new products etc. have a chain of events to relaunch the Company - hopefully in the right direction this time - let's hope.

I would have to agree that the company is in a much better position.

Although we were told more would come shortly at the 16th Oct Investor on reproductive health we also know via the product route map that by 2020-21 (when the new Illumina CE-IVD will also be launched) the product range will also include by then the following:
a) Pre-implantation genetic screening (PGS) – a technique for testing whether embryos have any problems with their chromosomes, which is thought to be the most common reason why IVF treatment fails.
b) Rhesus disease screens in which DNA from the unborn baby, found in the mother's blood, can be tested to determine if the foetus is at risk from the mother’s antibodies (when the mother’s blood is rhesus-negative and the foetus is rhesus-positive), which can destroy the red blood cells, causing jaundice, anaemia, miscarriage or stillbirth.
c) BRAC1 screens to pre-determine if a foetus is at risk of inheriting an altered (mutated) BRCA1 gene, which has been shown to increase a woman's chance of developing breast cancer and ovarian cancer.

Although the new Illumina test will only come in 2020, Premaitha has ALREADY taken a licence under Illumina’s patent pool agreement (PPA). This is important as PPA patents were pending in Brazil and India so clears. It allows Premaitha to also offer Illumina NGS lab services in interim to access the 80% of market on Illumina NGS. The Illumina CE-IVD would however I think allow Premaitha to expand more freely into US, Mexico and Australia. NOW through the settlement, in any non-PPA licensed territory (majority of Asia, Middle East, Africa and the Americas) Premaitha is free to be platform-agnostic providing tests for use on both Thermo Fisher and Illumina NGS platforms.

It should also be observed than compared to some stocks which have very much higher market capitalisations, Premaitha actually has a multitude of products already on the shelf.

The additional revenue streams above have yet to be included in the broker's revenue projections which pessimistically though DID include a softening of growth till the new CE-IVD. The unleashing of 80% opportunity referred (plus now free access to US, AUS, MEX) plus the additional products above apparently only provided 25% growth to £11.9m in the broker's forecast for 2021E. But I remain 'idealistic' that these revenue projections will be updated.

Despite these projections, which the Company has already distanced itself from, I note that in December 2016 Agilent Technologies bought Multiplicom for $72.8m. At the time Multiplicom had $6.5m sales so 11.2x EV/Sales. Hence suggesting that the current sp which is now heavily discounted.

On a side note there was an additional 400k shares bought this week at the placing price of 10p by an II separate to AR's additional 500k subscription. Given that Steve Myers passed the 8% threshold on the 23rd I suspect it was him. Hopefully we should recover to this placing price shortly and then mov

There was not some expected news I will give you that. Let's see whether this comes shortly.

I feel comfortable that with the annual report has already revealing the product route map, the Chairman already outlined how a wider planned strategy of debt forgiveness and warrant conversion with TMO, the CFO outlining the potential areas of geographical expansion pre and post Illumina CE-IVD development and the Vice Chairman the strategic opportunities now available to Premaitha as being a cross-platform molecular diagnostic firm; that the major elements of a new strategy have already been outlined. I would expect with the news of Company name change more elements would be revealed. I thought the AGM statement, aside from the potential trading update expected, was in keeping in style with last year's AGM statement.

A 6% share dilution has caused a 50% share value loss helped in no part to concerns over revenue forecasts (which the Company has already stated will be revised shortly following issue of a trading update); a brokers research notes (which the Company has already publicly distanced itself from and states will be updated probably by early November); and funding concerns (which the Chairman has already publicly addressed at the 16th presentation) and will in doubt comment further upon post the probable TMO debt forgiveness and warrant conversion exercise. Separate concerns raised about TMO strategic willingness to support the Company following the planned Illumina alliance have also been addressed via the probable TMO warrants conversion and the CEO's visit to the US to meet TMO. Your contribution in these discussions has also been duly noted.

It is fair to say that this 6% share dilution which has created a 50% share price loss has created a buying opportunity for some as progressively the concerns aired above have been responded to by the Company. With the Chairman buying further this week at 10p alongside Steve Myers I think we should gradually rise to the 10p placing floor level before long with the expected news flow of new reproductive product, trading update, revised broker forecast and potential TMO warrants. Hopefully this will allow us to move swiftly on from a fairly horrid few weeks.

All the best.

With the Company's name and TIDM shortly being changed to Yourgene Health plc and YGEN respectively, the "necessary administrative processes" alluded to in the 25th Oct RNS could allude to the Articles of Association having to be updated with the new Company Name. I also would have suspected that the TIDM might also require a publicity campaign to publicise the ticker symbol change which may or may not include other items. Although the RNS said "shortly" when this will happen who knows however I suspect we would get a RNS next week to publicise the date.

Florida I think after 5 weeks of this most people will have made up their mind one way or the other as to what has happened and what could have been done differently. Suffice to say that the share price appreciation in the months before the settlement was announced does suggest it was not a sudden change of heart on Illumina's side which was not worked to with Premaitha's solicitors. As you are aware as well the settlement announcement RNS was very brief and had led to many queries as to the ongoing relationship with TMO.

My main focus is on the future as the past has just created (another) buying opportunity for new entrants. I remain of the view that the current sp seems over sold post settlement, new oncology service and placing. Hopefully the gap in the next week will be closed to AR's additional 500k purchase price this week at 10p.

With the BoD already publicly distancing themselves from Finncap's research notes and suggesting that this will have to be updated shortly following a trading update which could (or could not) also include TMO warrants and debt relief hopefully we can put this episode behind us shortly.

I am actually quite happy with the name change as it does cover the announced new oncology lab service and expected reproductive health products. The other problem with the old ticker is that it would appear on the #NIPT twitter feed and wind the Downsyndrome groups up

All the best

I have to agree with Twix and that the current sp has more to do with the BoD than the market and I too would be extremely disappointed if we did not see better days before the 6th.

Shareholders had waited nearly 4 years for the litigation headwinds to pass and some better preparation for potential funding requirements and also in the communication of the strategic benefits of the deal to PIs should have been expected.

However these frustrations of LTHs now emerge as buying opportunities for others. I remain of the view that the current sp seems over sold given that the litigation has been settled and funding secured. With AR's purchase at 10p it seems inevitable that the gap will be closed eventually to this sp floor now that the placing period has been completed.

The expected material development that would have caused a trading update before the AGM I suspect is still being worked which should lead Finncap to revise their current pessimistic price target of 16p upwards within the next few weeks. Not to mention the probable debt forgiveness and exercise of TMO warrants (likely the 75m shares up to 12p). Premaitha - accidently - now stands very uniquely within the NIPT as being able to supply CE-IVD tests on both Illumina and TMO sequencers. The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 Billion by 2021 by when Premaitha's new Illumina CE-IVD will be launched.

Given that test volumes were 50k for 2018 I suspect that with the lifting of the litigation plus Asian expansion this should be over 80k for 2019. I can only track down test NIPT test volumes from 2016 cross-industry to see how this 80k should compare.
(a) Ariosa (Roche) including licensees: 213,300 tests (22% Market share)
(b) Sequenom: 153,900 tests
(c) Verinata (Illumina): 192,000 tests
(d) IP Pool (Sequenom & Illumina): 489,300 tests (50% Market share)
(e) Natera including licensees: 254,900 tests (26% Market share)

So my rough feel is that depending on the revised trading results Premaitha should be comfortably over 5% of the NIPT market. There is a growing consolidation within the NIPT market Ariosa Diagnostics was acquired by Roche), LifeCodexx was bought by GATC Biotech), Verinata Health, acquired by Illumina, Sequenom was acquired by LabCorp and finally Clarifgo acquired by Agilent Technologies. This combined with the now heavily discounted share price and clear strategic advantage provides opportunities for a 3rd Party to make an offer to clear the TMO warrants floor of 24.6p which I would support given recent events.